Ardea Biosciences (RDEA) Posts Q2 Loss of $0.49 Ex-Items, Misses Street Target
Ardea Biosciences, Inc. (Nasdaq: RDEA) reports Q2 EPS of $0.49, ex-items, versus the analyst estimate of ($0.12). Revenue for the quarter was $3.5 million, which compares to the estimate of $4.13 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S Foods Holdings (USFD) Files $100M IPO
- Consolidated-Tomoka Land (CTO) Reports Q4 EPS of $0.99, Offers Guidance
- Catalent (CTLT) Tops Q2 EPS by 2c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!